A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Razpipadon (Primary)
- Indications Dementia; Mental disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cerevel Therapeutics
- 01 Aug 2024 According to an AbbVie media release, AbbVie has acquired Cerevel Therapeutics.
- 02 Aug 2023 tAccording to a Cerevel Therapeutics media release, due to continued challenges that clinical sites have experienced in identifying the appropriate patient population for this novel indication, the timeline for this trial is under review.
- 28 Feb 2023 Planned End Date changed from 30 Jun 2023 to 1 Oct 2024.